KEPPRA Drug Patent Profile

When do Keppra patents expire, and when can generic versions of Keppra launch?

Keppra is a drug marketed by Ucb Inc and is included in four NDAs. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has twenty-nine patent family members in twenty-five countries.

The generic ingredient in KEPPRA is levetiracetam. There are thirty-five drug master file entries for this compound. Eighty-eight suppliers are listed for this compound. Additional details are available on the levetiracetam profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Keppra

A generic version of KEPPRA was approved as levetiracetam by MYLAN on November 4^th, 2008.

Summary for KEPPRA

International Patents:	29
US Patents:	1
Applicants:	1
NDAs:	4
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	118
Patent Applications:	4,578
Drug Prices:	Drug price information for KEPPRA
Drug Sales Revenues:	Drug sales revenues for KEPPRA
What excipients (inactive ingredients) are in KEPPRA?	KEPPRA excipients list
DailyMed Link:	KEPPRA at DailyMed

See drug prices for KEPPRA

See drug sales revenues for KEPPRA

Recent Clinical Trials for KEPPRA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Nebraska Methodist Health System	PHASE3
Ayal A. Aizer, MD	PHASE2
Sohag University	Phase 2

See all KEPPRA clinical trials

Pharmacology for KEPPRA

Physiological Effect

Decreased Central Nervous System Disorganized Electrical Activity

Paragraph IV (Patent) Challenges for KEPPRA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
KEPPRA	Tablets	levetiracetam	1000 mg	021035	1	2007-01-24

US Patents and Regulatory Information for KEPPRA

KEPPRA is protected by one US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ucb Inc	KEPPRA	levetiracetam	INJECTABLE;INTRAVENOUS	021872-001	Jul 31, 2006	AP	RX	Yes	Yes
Ucb Inc	KEPPRA XR	levetiracetam	TABLET, EXTENDED RELEASE;ORAL	022285-001	Sep 12, 2008	AB	RX	Yes	No	7,858,122		Y
Ucb Inc	KEPPRA	levetiracetam	TABLET;ORAL	021035-001	Nov 30, 1999	AB	RX	Yes	No	8,802,142*PED				Y
Ucb Inc	KEPPRA XR	levetiracetam	TABLET, EXTENDED RELEASE;ORAL	022285-002	Feb 12, 2009	AB	RX	Yes	Yes	7,858,122		Y
Ucb Inc	KEPPRA	levetiracetam	SOLUTION;ORAL	021505-001	Jul 15, 2003	AA	RX	Yes	Yes
Ucb Inc	KEPPRA	levetiracetam	TABLET;ORAL	021035-004	Jan 6, 2006	AB	RX	Yes	Yes	8,802,142*PED				Y
Ucb Inc	KEPPRA	levetiracetam	TABLET;ORAL	021035-003	Nov 30, 1999	AB	RX	Yes	No	8,802,142*PED				Y

Expired US Patents for KEPPRA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Ucb Inc	KEPPRA	levetiracetam	SOLUTION;ORAL	021505-001	Jul 15, 2003	4,837,223
Ucb Inc	KEPPRA	levetiracetam	TABLET;ORAL	021035-002	Nov 30, 1999	4,837,223
Ucb Inc	KEPPRA	levetiracetam	TABLET;ORAL	021035-003	Nov 30, 1999	4,837,223
Ucb Inc	KEPPRA	levetiracetam	TABLET;ORAL	021035-001	Nov 30, 1999	4,837,223

EU/EMA Drug Approvals for KEPPRA

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
UCB Pharma SA	Keppra	levetiracetam	EMEA/H/C/000277Keppra is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy.Keppra is indicated as adjunctive therapy:in the treatment of partial-onset seizures with or without secondary generalisation in adults, children and infants from one month of age with epilepsy;in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy;in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.	Authorised	no	no	no	2000-09-29
Pfizer Europe MA EEIG	Levetiracetam Hospira	levetiracetam	EMEA/H/C/002783Levetiracetam Hospira is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in adults and adolescents from 16 years of age with newly diagnosed epilepsy.Levetiracetam Hospira is indicated as adjunctive therapyin the treatment of partial onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy.in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with Idiopathic Generalised Epilepsy.Levetiracetam Hospira concentrate is an alternative for patients when oral administration is temporarily not feasible.	Authorised	yes	no	no	2014-01-07
Accord Healthcare S.L.U.	Levetiracetam Accord	levetiracetam	EMEA/H/C/002290Levetiracetam is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy.Levetiracetam is indicated as adjunctive therapy:in the treatment of partial-onset seizures with or without secondary generalisation in adults, children and infants from one month of age with epilepsy;in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy;in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.	Authorised	yes	no	no	2011-10-03
Pharmathen S.A.	Matever	levetiracetam	EMEA/H/C/002024Matever is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy.Matever is indicated as adjunctive therapy:in the treatment of partial-onset seizures with or without secondary generalisation in adults, children and infants from one month of age with epilepsy;in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy;in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.	Authorised	yes	no	no	2011-10-03
Actavis Group PTC ehf	Levetiracetam Actavis	levetiracetam	EMEA/H/C/002355Levetiracetam Actavis is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy.Levetiracetam Actavis is indicated as adjunctive therapy:in the treatment of partial-onset seizures with or without secondary generalisation in adults, children and infants from one month of age with epilepsy;in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy;in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.	Authorised	yes	no	no	2011-10-03
Actavis Group PTC ehf	Levetiracetam Actavis Group	levetiracetam	EMEA/H/C/002305Levetiracetam Actavis Group is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy.Levetiracetam Actavis Group is indicated as adjunctive therapy:in the treatment of partial-onset seizures with or without secondary generalisation in adults, children and infants from 1 month of age with epilepsy;in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy;in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.	Authorised	yes	no	no	2011-12-04
Sun Pharmaceutical Industries Europe B.V.	Levetiracetam Sun	levetiracetam	EMEA/H/C/002051Levetiracetam Sun is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy.Levetiracetam Sun is indicated as adjunctive therapy:in the treatment of partial-onset seizures with or without secondary generalisation in adults and children from four years of age with epilepsy;in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy;in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.Levetiracetam Sun concentrate is an alternative for patients when oral administration is temporarily not feasible.	Authorised	yes	no	no	2011-12-14

International Patents for KEPPRA

See the table below for patents covering KEPPRA around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	45348
Austria	45567
Australia	4252985
Australia	4253085
Australia	574175
Australia	574465
Bulgaria	47497	METHOD FOR PREPARING OF (L)- ALPHA- ETHYL- 2- OXO- 1- PYROLIDINEACETAMIDE

Supplementary Protection Certificates for KEPPRA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0162036	SPC/GB00/030	United Kingdom		SPC/GB00/030: 20050514, EXPIRES: 20100514
0162036	2000C/032	Belgium		PRODUCT NAME: LEVETIRACETAM; NAT. REGISTRATION NO/DATE: EU/1/00/146/001 20000929; FIRST REGISTRATION: CH 55297 20000329
0162036	C300028	Netherlands		PRODUCT NAME: LEVETIRACETAM; REGISTRATION NO/DATE: EU/1/00/146/001 - EU/1/00/146/026 20000929

Keppra Market Dynamics, Patent Expiration, Generic Competition, and Financial Trajectory

Last updated: August 1, 2026

Keppra, the branded version of levetiracetam, moved from a high-growth epilepsy product to a mature, heavily genericized medicine after U.S. patent protection ended. UCB retains the Keppra brand, but the commercial market is now driven primarily by generic levetiracetam volume, hospital purchasing, formulation differences, and international pricing. The product remains clinically important because of broad seizure indications, intravenous availability, low drug-interaction burden, and extensive physician familiarity. Its financial contribution to UCB is materially lower than during the pre-generic period.

What is Keppra and who markets it?

Keppra is levetiracetam, an antiseizure medicine developed and commercialized by UCB. The U.S. Food and Drug Administration approved immediate-release Keppra tablets, oral solution, and injection in 1999. The product was initially approved for adjunctive treatment of partial-onset seizures in adults and later received broader indications and pediatric approvals. FDA labeling now covers several seizure types and age groups, depending on dosage form and indication (FDA, 2024a).

UCB markets Keppra and certain related formulations. Generic levetiracetam is supplied by multiple manufacturers, including large generic companies and regional suppliers. Common generic dosage forms include:

• Immediate-release tablets
• Extended-release tablets
• Oral solution
• Intravenous injection
• Oral and injectable products for hospital use

Levetiracetam is commercially distinct from UCB’s later epilepsy products, including Briviact, which contains brivaracetam. Briviact was developed as a newer-generation product with the same broad therapeutic area but a separate active ingredient and patent estate.

How large is the Keppra and levetiracetam market?

The branded Keppra market is substantially smaller than the total levetiracetam market. Generic substitution has shifted most prescription volume away from UCB’s branded product in the United States and other markets where substitution is permitted.

The market has several revenue pools:

Market segment	Main commercial driver	Competitive condition
U.S. generic oral levetiracetam	High prescription volume and low unit price	Highly competitive
U.S. hospital injection	Supply reliability, contracts, and shortages	Competitive, with episodic pricing pressure
International branded Keppra	Local reimbursement and brand loyalty	Varies by country
Keppra XR and generic extended-release	Dosing convenience and adherence	More limited than immediate-release
Specialty and pediatric use	Liquid formulations and clinical familiarity	Generic competition remains strong
Briviact	Differentiation and newer patent protection	Branded specialty competition

Levetiracetam benefited from broad use across neurology, emergency medicine, inpatient seizure management, and perioperative settings. Its lack of major hepatic enzyme-inducing effects supports use in patients taking multiple medicines. Those characteristics support persistent demand even after loss of exclusivity.

The market is volume-stable but price-declining. Generic entry typically reduces the originator’s price and share, while total treated-patient volume may remain resilient because levetiracetam is embedded in clinical practice.

When did Keppra lose U.S. exclusivity?

Keppra lost its principal U.S. small-molecule patent protection in the late 2000s, with generic competition expanding after FDA approvals of abbreviated new drug applications. The immediate-release market was substantially genericized by the early 2010s.

Keppra U.S. regulatory timeline

Event	Date
FDA approval of Keppra immediate-release product	November 1999
U.S. compound patent protection	Expired in the late 2000s
Generic levetiracetam approvals and market entry	Late 2000s to early 2010s
Keppra XR approval	2008
U.S. generic erosion of immediate-release sales	Primarily early 2010s
Current market status	Mature generic market

The precise commercial erosion date differed by formulation, dosage strength, distributor, and litigation outcome. Immediate-release products faced the earliest and most intense competition. Extended-release products retained separate formulation and regulatory considerations, but they did not preserve the original Keppra franchise economics.

The FDA Orange Book remains the relevant source for listed patents, regulatory exclusivity, and reference-product information (FDA, 2024b). For a mature medicine such as Keppra, the key commercial issue is no longer basic molecule exclusivity. It is whether any formulation, device, manufacturing, or product-specific patent can support meaningful protection.

What patents protect Keppra and levetiracetam?

The core levetiracetam compound patent was the principal source of early exclusivity. That protection has expired. Later patents and regulatory protections covered specific formulations, dosage forms, or uses rather than restoring broad exclusivity for the active ingredient.

Patent protection by category

Protection category	Commercial relevance today
Core levetiracetam compound patent	Expired; generic entry enabled
Immediate-release tablet patents	Limited or expired relevance
Extended-release formulation patents	May affect specific products, but do not block immediate-release generics
Oral solution patents	Generally weak against alternative generic formulations
Intravenous formulation patents	Product-specific; procurement competition remains
Method-of-use patents	Narrow because core seizure indications are established
Manufacturing patents	Can raise process barriers but rarely block all generic supply

The compound patent’s expiration allowed generic manufacturers to rely on the reference product’s safety and efficacy findings through the ANDA pathway. Generic applicants could challenge listed patents through Paragraph IV certifications or wait for patent expiration under other certification pathways (FDA, 2024c).

UCB’s patent strategy later shifted toward differentiated epilepsy medicines such as brivaracetam rather than relying on Keppra to maintain broad exclusivity.

What is the Orange Book status of Keppra?

Keppra is a reference-listed drug in the FDA’s Orange Book framework. Generic levetiracetam applicants use Keppra as the reference product for relevant dosage forms and strengths.

The Orange Book records the patents and exclusivity information that affect abbreviated applications. For a mature product, Orange Book status must be assessed separately for:

• Keppra immediate-release tablets
• Keppra oral solution
• Keppra injection
• Keppra XR extended-release tablets
• Strength-specific listings
• Formulation-specific patents
• Product-specific exclusivity periods

The presence of an Orange Book patent does not necessarily prevent generic launch. A generic company may certify that the patent is invalid or not infringed under Paragraph IV. The brand holder may then file patent litigation, triggering the statutory 30-month stay in appropriate circumstances under the Hatch-Waxman Act.

Which companies challenged Keppra patents?

Generic competition came from multiple ANDA applicants rather than a single challenger. The levetiracetam market includes manufacturers such as Teva, Mylan, Sandoz, Dr. Reddy’s Laboratories, Lupin, Zydus, Aurobindo, and other suppliers, depending on the product, strength, and period reviewed.

The competitive pattern was typical of a high-volume small molecule:

1. Generic applicants filed ANDAs for the principal dosage forms.
2. Some applicants used Paragraph IV certifications against listed patents.
3. Patent disputes were resolved through litigation, settlement, or expiration.
4. FDA approvals expanded across multiple strengths and formulations.
5. Price competition intensified as additional suppliers entered.

The most significant commercial event was the expiration of broad protection for levetiracetam itself. Once multiple generic suppliers were approved, UCB could not preserve the original Keppra revenue base through brand pricing alone.

What formulation patents protect Keppra XR?

Keppra XR is an extended-release version of levetiracetam. Its formulation was designed to support once-daily dosing rather than the more frequent dosing used by immediate-release products.

Formulation patents can protect:

• Release profile
• Matrix or coating architecture
• Excipient composition
• Tablet manufacturing process
• Drug-release performance
• Dosage regimen linked to the formulation

These rights are narrower than a compound patent. They may delay generic extended-release entry or create litigation exposure, but they do not prevent generic immediate-release levetiracetam from competing with the broader Keppra franchise.

For investors and licensing teams, the key distinction is between franchise protection and product protection. A formulation patent may protect Keppra XR for a defined period, but it does not preserve the economics of all levetiracetam products.

What FDA exclusivity did Keppra receive?

Keppra received standard regulatory protections associated with a new molecular entity and later pediatric regulatory activity. Those periods ended long before the current market phase.

FDA exclusivity can include:

• Five-year new chemical entity exclusivity
• Three-year exclusivity for qualifying new clinical investigations
• Six-month pediatric exclusivity
• Orphan-drug exclusivity, if applicable
• Exclusivity tied to certain dosage forms or indications

Keppra’s commercial lifecycle was primarily governed by patent protection and subsequent generic entry. FDA exclusivity did not create a continuing barrier to generic levetiracetam in the current market (FDA, 2024d).

How did generic entry affect UCB’s Keppra revenue?

Keppra generated blockbuster-level revenue before generic erosion. UCB reported Keppra sales of approximately €1 billion annually around the peak period before the franchise entered sustained decline. After generic competition, reported sales fell sharply as prescriptions shifted to lower-priced alternatives and branded demand weakened.

Financial trajectory

Period	Keppra financial position	Principal driver
Late 1990s to early 2000s	Rapid growth	New indication expansion and physician adoption
Mid-to-late 2000s	Peak commercial period	Broad epilepsy use and patent protection
Early 2010s	Rapid decline	U.S. generic entry and price erosion
Mid-2010s	Mature branded product	International sales and residual brand demand
2020s	Legacy franchise	Generic market dominance and limited brand growth

UCB’s group revenue increasingly depended on newer products, including Vimpat historically and Briviact, Fintepla, Bimzelx, and other growth assets in later periods. Keppra’s role shifted from a primary growth engine to a cash-generating legacy product with lower strategic priority (UCB, 2011; UCB, 2024).

Exact Keppra sales are not consistently disclosed as a standalone line item in recent UCB reporting. The company’s reporting emphasis has moved toward newer growth products and broader therapeutic-area performance.

What generic entry risks exist for Keppra?

Generic entry risk is no longer a future event for immediate-release Keppra. It is an established market condition.

The remaining commercial risks include:

• Further price compression among generic suppliers
• Loss of remaining branded prescriptions
• Hospital purchasing substitution
• Pharmacy benefit manager pressure
• Product shortages that can temporarily shift share between suppliers
• Generic entry into extended-release presentations
• International reference-pricing effects
• Regulatory changes favoring substitution

The main countervailing factors are clinical familiarity, availability of multiple dosage forms, hospital protocol adoption, and the need for reliable supply. These factors support persistent levetiracetam demand but do not restore originator pricing power.

Is biosimilar risk relevant to Keppra?

No. Keppra contains levetiracetam, a chemically synthesized small molecule. It is not a biologic and does not face biosimilar competition under the Public Health Service Act.

The relevant competitive pathway is the abbreviated new drug application, not the 351(k) biosimilar pathway. Generic applicants demonstrate pharmaceutical equivalence and bioequivalence to the reference product for the applicable dosage form (FDA, 2024c).

This distinction matters commercially:

Issue	Keppra
Product type	Small-molecule drug
Competitive pathway	ANDA
Biosimilar pathway	Not applicable
Interchangeability framework	State and pharmacy substitution rules
Primary risk	Generic price and volume erosion

How does Keppra compare with Briviact?

Keppra and Briviact are both UCB epilepsy products, but their patent and commercial positions differ materially.

Attribute	Keppra	Briviact
Active ingredient	Levetiracetam	Brivaracetam
Product age	Approved in 1999	Approved in 2016
U.S. market status	Predominantly genericized	Branded product with active exclusivity considerations
Formulations	Tablets, oral solution, injection, XR	Tablets, oral solution, injection
Main value proposition	Broad use, familiarity, low cost	Newer branded therapy and differentiated positioning
Revenue profile	Legacy and declining	More recent growth and lifecycle management
Generic risk	Established and extensive	Future risk tied to patent and exclusivity expiry

Briviact is not a patent extension of Keppra. It is a separate molecule intended to support UCB’s epilepsy franchise after Keppra’s loss of exclusivity.

What licensing deals affect Keppra?

Keppra’s development and commercialization are associated with UCB’s long-term ownership and commercialization of levetiracetam. The product’s commercial history is linked to UCB’s acquisition and integration of assets from companies involved in the compound’s development, including the broader lineage of UCB’s epilepsy portfolio.

The important business point is that Keppra is not dependent on a current co-commercialization arrangement comparable to many newer partnered medicines. Generic levetiracetam is supplied independently by multiple manufacturers under FDA-approved ANDAs and corresponding foreign regulatory approvals.

Licensing value today is limited for the basic molecule. Potential transaction value would more likely involve:

• Regional brand rights
• Hospital injectable supply
• Specialty formulations
• Manufacturing capacity
• Distribution rights in markets where brand recognition remains meaningful

What patent litigation affects Keppra?

The major litigation risk occurred during the transition from originator protection to generic competition. Hatch-Waxman litigation could involve validity, infringement, claim construction, formulation claims, and the timing of generic approval.

The current litigation profile is more limited because:

• Core molecule protection has expired.
• Multiple generic suppliers are established.
• Generic levetiracetam is widely approved.
• Brand-side damages exposure is lower after prolonged market commoditization.
• Any remaining disputes are more likely to concern specific formulations, labeling, supply, or manufacturing rights.

A current diligence review should separate historical Paragraph IV litigation from live disputes. Historical litigation can explain entry timing, but it does not establish a present barrier to generic levetiracetam.

How strong is the Keppra patent estate?

The Keppra patent estate is commercially weak for broad market exclusivity and moderate only for narrow product features.

Patent-strength assessment

Patent category	Assessment
Core active ingredient	Weak; expired
Immediate-release products	Weak; generic substitution established
Extended-release formulation	Narrow, potentially relevant to specific presentations
Injectable product	Limited product-specific protection
Method of use	Narrow and vulnerable to established generic labeling
Manufacturing process	Potentially useful for supply or cost, not broad market control
International rights	Country-specific and largely mature

The estate’s residual value lies in operational and formulation details rather than control of levetiracetam as a therapeutic class.

What are the likely generic launch scenarios?

For immediate-release levetiracetam, the launch scenario has already occurred: multiple generic suppliers compete on price, contracts, and supply continuity.

For extended-release or specialized presentations, the relevant scenarios are:

Continued multi-source competition

Several manufacturers maintain approval and compete for pharmacy, wholesaler, and hospital contracts. Prices remain low, and no single supplier controls the market.

Supplier consolidation

Some companies exit because margins are insufficient, leaving fewer approved suppliers. This can improve pricing temporarily but increases shortage risk.

Hospital-led substitution

Hospitals favor generic injectable levetiracetam when clinical protocols, pharmacy committees, and supply contracts support substitution.

Brand preservation in narrow segments

Keppra may retain limited use where prescribers, patients, or institutions value branded supply, although the price premium limits this opportunity.

What geographic markets remain commercially relevant?

Keppra’s value varies by jurisdiction.

• United States: mature generic market with limited branded economics.
• European Union: broad generic penetration, national reimbursement controls, and reference pricing.
• Japan: branded and generic dynamics depend on local approval, reimbursement, and substitution rules.
• Emerging markets: brand recognition may remain stronger, but prices and tender systems limit margins.
• Hospital markets: injectable supply and procurement reliability can matter more than brand identity.

Patent expiry is country-specific. A global freedom-to-operate review must examine national patent registers, supplementary protection certificates, pediatric extensions, regulatory exclusivity, and local formulation rights.

What is the investment outlook for Keppra?

Keppra is a defensive, mature product rather than a growth asset. Its economic profile is characterized by:

• High clinical familiarity
• Persistent prescription demand
• Low originator pricing power
• Generic volume dominance
• Limited patent-based upside
• Potential supply-chain value in selected markets
• Declining strategic importance within UCB’s portfolio

Revenue exposure is more relevant to generic manufacturers, contract suppliers, and hospital distributors than to UCB’s growth valuation. For UCB, the principal investment question is whether the legacy epilepsy franchise supports newer-product adoption, particularly Briviact and other pipeline or marketed assets.

Key Takeaways

• Keppra is the branded form of levetiracetam, a small-molecule antiseizure medicine.
• FDA approval occurred in 1999, and broad U.S. generic entry followed patent expiry in the late 2000s.
• Immediate-release levetiracetam is now a mature, multi-source generic market.
• Keppra XR and other formulations may have had narrower protection, but formulation rights do not restore compound-level exclusivity.
• Biosimilar risk does not apply; ANDA-based generic competition is the relevant pathway.
• UCB’s Keppra revenue declined sharply after generic entry and is no longer a primary growth driver.
• Residual commercial value depends on international brands, hospital injection supply, formulation niches, and distribution.
• Briviact is UCB’s separate, newer branded epilepsy product and has a different patent and lifecycle profile.

FAQs

Is Keppra still under patent?

The broad U.S. patent protection for levetiracetam has expired. Specific formulation or product patents must be assessed separately by dosage form and jurisdiction.

Can a generic company substitute levetiracetam for Keppra?

Generic substitution depends on FDA approval, product equivalence, state pharmacy law, payer policy, and the specific dosage form. Immediate-release generic levetiracetam is widely available.

Does Keppra have biosimilars?

No. Keppra is a chemically synthesized small molecule. Its competitors are generic levetiracetam products approved through the ANDA pathway.

Why do hospitals still use branded Keppra?

Hospitals may retain branded products because of formulary preference, supply contracts, protocol continuity, procurement arrangements, or product-specific purchasing decisions. Generic levetiracetam is widely used.

Is Briviact a patent-protected version of Keppra?

No. Briviact contains brivaracetam, a different active ingredient. It is a separate product developed within UCB’s epilepsy portfolio.

References

1. U.S. Food and Drug Administration. (2024a). Keppra: Prescribing information. FDA.

2. U.S. Food and Drug Administration. (2024b). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.

3. U.S. Food and Drug Administration. (2024c). Abbreviated new drug application approvals and generic drug development. FDA.

4. U.S. Food and Drug Administration. (2024d). Market exclusivity and patent protections for approved drugs. FDA.

5. UCB. (2011). Annual report 2010. UCB S.A.

6. UCB. (2024). Annual report 2023. UCB S.A.

DrugChatter Q&A for KEPPRA

Does keppra still have xclusivity in japan?
When did keppra loose patent?
How much is keppra with insurance?
Keppra seizure medication?
Where is keppra manufactured?